{"id":"lisinopril-hctz","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"5-10","effect":"Hypokalemia"},{"rate":"5-10","effect":"Hyperuricemia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"3-5","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL419213","moleculeType":"Small molecule","molecularWeight":"441.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lisinopril blocks ACE, preventing conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion. HCTZ acts as a thiazide diuretic, increasing urinary sodium and water excretion to decrease blood volume and peripheral vascular resistance. Together, these complementary mechanisms provide synergistic antihypertensive effects.","oneSentence":"Lisinopril inhibits angiotensin-converting enzyme to reduce blood pressure, while HCTZ is a thiazide diuretic that lowers blood pressure by reducing fluid volume and sodium reabsorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:05.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"}]},"trialDetails":[{"nctId":"NCT05049616","phase":"PHASE4","title":"Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-10-18","conditions":"Hypertension in Pregnancy, Postpartum Preeclampsia","enrollment":70},{"nctId":"NCT00006294","phase":"","title":"Genetics of Hypertension Associated Treatments (GenHAT)","status":"COMPLETED","sponsor":"Donna Arnett, 257-5678","startDate":"1999-09","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":37939},{"nctId":"NCT01326676","phase":"PHASE3","title":"Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2011-02","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT01313702","phase":"PHASE3","title":"Single Pill to Avert Cardiovascular Events","status":"WITHDRAWN","sponsor":"Hospital do Coracao","startDate":"2012-10","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT03461003","phase":"PHASE4","title":"N-of-1 Trials In Children With Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-02","conditions":"Pediatric Hypertension","enrollment":49},{"nctId":"NCT02774460","phase":"PHASE4","title":"The Precision Hypertension Care Study","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2017-02-20","conditions":"Hypertension","enrollment":280},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT01984164","phase":"PHASE2","title":"CAndesartan vs LIsinopril Effects on the BRain","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-08-20","conditions":"Hypertension, Mild Cognitive Impairment","enrollment":176},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00283686","phase":"PHASE3","title":"HALT Progression of Polycystic Kidney Disease Study A","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2006-01","conditions":"Kidney, Polycystic","enrollment":558},{"nctId":"NCT00673790","phase":"PHASE4","title":"The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-05-15","conditions":"Hypertension","enrollment":537},{"nctId":"NCT02412761","phase":"NA","title":"Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2013-06","conditions":"Essential Hypertension","enrollment":42},{"nctId":"NCT00567307","phase":"PHASE2","title":"Polypill For Prevention of Cardiovascular Disease","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2009-01","conditions":"Cardiovascular Disease","enrollment":216},{"nctId":"NCT01996085","phase":"NA","title":"Non-invasive Haemodynamic Assessment in Hypertension","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2013-01","conditions":"Arterial Hypertension","enrollment":144},{"nctId":"NCT00994253","phase":"PHASE4","title":"Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics","status":"WITHDRAWN","sponsor":"Corewell Health East","startDate":"2009-08","conditions":"Hypertension, Diabetes Type 2","enrollment":""},{"nctId":"NCT00171574","phase":"PHASE4","title":"Antiproteinuric Effect of Valsartan and Lisinopril","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Hypertension, Diabetic Nephropathy","enrollment":124},{"nctId":"NCT01994408","phase":"PHASE1, PHASE2","title":"Default BP Medication Intensification","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2013-11","conditions":"Hypertension","enrollment":3},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01658657","phase":"NA","title":"A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-10","conditions":"Hypertension, Plasma Renin Activity","enrollment":17},{"nctId":"NCT01258764","phase":"NA","title":"Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril","status":"COMPLETED","sponsor":"Scripps Translational Science Institute","startDate":"2010-11","conditions":"Hypertension, Grade 1, Hypertension Treatment, N of 1 Study Design","enrollment":2},{"nctId":"NCT02336607","phase":"NA","title":"The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Hypertension","enrollment":529},{"nctId":"NCT00459056","phase":"PHASE3","title":"The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients","status":"COMPLETED","sponsor":"St. Paul Heart Clinic","startDate":"2007-04","conditions":"Abdominal Obesity, Hypertension","enrollment":25},{"nctId":"NCT01506505","phase":"NA","title":"The Evening Versus Morning Polypill Utilization Study","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2012-07","conditions":"Cardiovascular Disease, Cerebrovascular Disease, Peripheral Arterial Disease","enrollment":78},{"nctId":"NCT01831700","phase":"PHASE1","title":"Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-10","conditions":"Fasting","enrollment":48},{"nctId":"NCT01827878","phase":"PHASE1","title":"Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-10","conditions":"Fed","enrollment":48},{"nctId":"NCT00605072","phase":"PHASE2","title":"The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2008-01","conditions":"Cognitive Impairment, Hypertension, Aging","enrollment":53},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99},{"nctId":"NCT01057537","phase":"PHASE3","title":"UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2010-06","conditions":"Cardiovascular Diseases","enrollment":2004},{"nctId":"NCT00171535","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Hypertension","enrollment":130},{"nctId":"NCT00171600","phase":"PHASE4","title":"Antialbuminuric Effects of Valsartan and Lisinopril","status":"TERMINATED","sponsor":"Novartis","startDate":"2005-07","conditions":"Hypertension, Early Diabetic Nephropathy","enrollment":54},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00631514","phase":"PHASE4","title":"Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)","status":"COMPLETED","sponsor":"University of Split","startDate":"2005-01","conditions":"Hypertension","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prinivil","Hydrochlorothiazide"],"phase":"phase_3","status":"active","brandName":"Lisinopril + HCTZ","genericName":"Lisinopril + HCTZ","companyName":"St. Paul Heart Clinic","companyId":"st-paul-heart-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lisinopril inhibits angiotensin-converting enzyme to reduce blood pressure, while HCTZ is a thiazide diuretic that lowers blood pressure by reducing fluid volume and sodium reabsorption. Used for Hypertension, Heart failure with reduced ejection fraction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}